trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Amlodipine besylate is a long-acting calcium channel blocker.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
2 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Amlodipine besylate is a long-acting calcium channel blocker?

Yes. Amlodipine besylate is widely documented in clinical literature as a long-acting calcium channel blocker used in the management of hypertension.

Verdict: SUPPORTED · 2 sources for, 0 against · Last checked

The analysis

The retrieved papers consistently confirm that amlodipine (and amlodipine besylate) is a long-acting calcium channel blocker characterized by an extended plasma half-life and once-daily dosing requirements.

Evidence for · 2
AMLODIPINE, A LONG‐ACTING CALCIUM CHANNEL BLOCKER, ATTENUATES MORNING BLOOD PRESSURE RISE IN HYPERTENSIVE PATIENTS
1999
This study explicitly characterizes amlodipine as a long-acting calcium channel blocker with a plasma half-life of 36 hours.
Get citation
Ishimitsu, T., Minami, J., Kawano, Y., Numabe, A., & Takishita, S. (1999). AMLODIPINE, A LONG‐ACTING CALCIUM CHANNEL BLOCKER, ATTENUATES MORNING BLOOD PRESSURE RISE IN HYPERTENSIVE PATIENTS. doi.org. https://doi.org/10.1046/j.1440-1681.1999.03072.x

See more details
More for · 1
Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.
2021
This paper discusses amlodipine besylate as a calcium channel blocker used for hypertension treatment in long-acting drug delivery systems.
Get citation
N, D. T., HC, L., R, Q., DI, V., X, L., CYX, C., & A, G. (2021). Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.. doi.org. https://doi.org/10.1016/j.nano.2021.102417

What does the evidence say?

The retrieved papers consistently confirm that amlodipine (and amlodipine besylate) is a long-acting calcium channel blocker characterized by an extended plasma half-life and once-daily dosing requirements.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work